Genome&Company's 'GEN-001' Selected for Major Poster Presentation at US Conference

Genome&Company's immuno-oncology drug 'GEN-001' clinical phase 2 interim results poster has been selected as a major poster at a leading U.S. conference.

A representative from Genome & Company is presenting the cutoff data poster of the Phase 2 clinical trial for the microbiome immuno-oncology drug 'GEN-001' targeting gastric cancer at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium (ASCO GI 2024).
[Photo by Genome & Company]

Genome&Company announced on the 23rd that at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (ASCO GI 2024) held from the 18th to 20th (local time) in San Francisco, California, USA, the phase 2 cutoff data poster of ‘GEN-001’, a microbiome-based immuno-oncology drug under development for gastric cancer, was selected as one of the ‘Top 5’ posters among those presented at the conference.

The poster was chosen as one of the Top 5 out of a total of 220 posters presented at ASCO GI, and was also presented in a separate 'Poster Walk' session. Companies participating in the session have the opportunity to introduce and discuss their posters orally, allowing for in-depth discussions on the research.

Jisoo Bae, CEO of Genome&Company, said, “The reason for being selected as a Top 5 poster is due to the very high unmet medical need in advanced gastric cancer and the encouraging objective response rate (ORR) of 37.5% observed in patients who had previously received immuno-oncology treatments. Also, the combination therapy of a microbiome-based novel immuno-oncology drug with low risk of side effects and existing programmed cell death protein (PD)-(L)1 class immuno-oncology drugs demonstrated the potential for synergy surpassing PD-(L)1 immuno-oncology monotherapy, which seems to have attracted the attention of researchers attending this conference.” ORR refers to the proportion of patients showing an anti-cancer response with a certain amount of tumor reduction.

Professor Ji-yeon Lee of the Department of Hematology and Oncology at Samsung Medical Center, who led the clinical trial, explained, “The combination therapy of the microbiome immuno-oncology drug ‘GEN-001’ and PD-(L)1 class immuno-oncology drugs showed meaningful therapeutic effects and potential survival extension. It is encouraging that a 37.5% ORR was confirmed even in some PD-L1 positive patients who had previously failed immuno-oncology treatment. We will continue to demonstrate results to establish this as a third-line treatment through further clinical studies.”